MarketBeat Week in Review – 06/29 – 07/03 Moderna (NASDAQ:MRNA) reported second-quarter revenue of $145 million, exceeding the high end of its prior guidance range, while continuing to reduce costs and advance programs spanning respiratory vaccines, oncology and rare diseases.
The company posted a net loss of $782 million, or $1.97 per share, compared with a loss of $825 million, or $2.13 per share, a year earlier
Moderna ended the quarter with $6.9 billion in cash and investments, down from $7.5 billion at the end of the first quarter as it funded operations and pipeline development. – Short Squeeze Alert—Moderna Stock Surges on New Strategy Chief Executive Officer Stéphane Bancel said the second quarter is typically light for seasonal vaccine sales. He said Moderna reduced cash costs by 10% from the second quarter of 2025 and remained focused on financial discipline while preparing for the 2026-2027 vaccination season. Revenue Outlook and Cost Reductions Chief Financial Officer Jamey Mock said revenue rose 2% year over year in the quarter.
The geographic mix was 60% U.S. and 40% international, while first-half revenue totaled approximately $500 million, with international markets accounting for 69% of sales. – The S&P 500’s 3 Best-Performing Stocks So Far in 2026 Moderna reiterated its expectation for revenue growth of up to 10% in 2026. The company expects a roughly even split between U.S. and international revenue for the full year and said third-quarter revenue should represent about 55% of second-half revenue. Management said long-term strategic partnerships in markets including the U.K., Canada and Australia contributed to first-half international performance.